HI-Bio is a company.
HI-Bio has raised $215.0M across 2 funding rounds.
Key people at HI-Bio.
HI-Bio has raised $215.0M in total across 2 funding rounds.
Key people at HI-Bio.
HI-Bio has raised $215.0M in total across 2 funding rounds.
HI-Bio's investors include ARCH Venture Partners.
HI-Bio (Human Immunology Biosciences) is a clinical-stage biotechnology company focused on developing precision medicines for patients with severe immune-mediated diseases (IMDs), such as autoimmune and inflammatory disorders. Its lead therapeutic candidate, felzartamab, targets multiple indications including antibody-mediated rejection, IgA nephropathy, lupus nephritis, and primary membranous nephropathy. The company aims to transform clinical immunology by moving away from one-size-fits-all treatments toward targeted therapies that address cellular drivers of disease. HI-Bio serves patients with high unmet medical needs and operates clinical development programs in both Europe and the United States. The company has demonstrated strong growth momentum, culminating in its acquisition by Biogen in 2024 for up to $1.8 billion, validating its innovative approach and pipeline[1][2][3].
Founded in 2021 and based in South San Francisco, HI-Bio was incubated by ARCH Venture Partners and Monograph Capital, with additional funding from Jeito Capital and other investors. The founding team includes experienced biotech and investment professionals, with CEO Travis Murdoch bringing expertise from SoftBank investment advisory. The idea emerged from the recognition that immune-mediated diseases require more precise therapeutic approaches leveraging genetics and immunology. Early traction was marked by licensing two drug candidates from German biotech MorphoSys and raising $120 million in initial financing. The company quickly advanced its lead candidate, felzartamab, into Phase 2 clinical trials, establishing itself as a promising player in autoimmune drug development[2][3][4].
HI-Bio rides the growing trend toward precision medicine and targeted immunotherapies, a field gaining momentum due to advances in genetics, molecular biology, and computational drug discovery. The timing is critical as immune-mediated diseases represent a significant unmet medical need with limited effective treatments. Market forces such as increasing prevalence of autoimmune disorders, regulatory support for innovative therapies, and growing investment in biotech innovation favor HI-Bio’s approach. By developing therapies that precisely modulate immune responses, HI-Bio contributes to shifting the immunology landscape from broad immunosuppression to personalized treatment, influencing both clinical practice and drug development paradigms[2][3].
Following its acquisition by Biogen, HI-Bio is positioned to accelerate the clinical development and commercialization of its precision therapies, potentially expanding into additional immune-mediated indications. Future trends shaping its journey include advances in biomarker-driven patient stratification, integration of AI in drug discovery, and increasing demand for safer, more effective autoimmune treatments. HI-Bio’s influence is likely to grow as it helps set new standards for targeted immunology therapies, driving improved patient outcomes and inspiring further innovation in the biotech ecosystem. This trajectory ties back to its founding mission of transforming clinical immunology through precision medicine[1][2][3].
HI-Bio has raised $215.0M across 2 funding rounds. Most recently, it raised $95.0M Series B in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $95.0M Series B | ARCH Venture Partners | |
| Oct 1, 2022 | $120.0M Series A | ARCH Venture Partners |
